Cadila: Rebound in domestic formulations to add to US sales, drive earnings

Shares of Cadila Healthcare gained 5.6 per cent and scaled fresh 52-week high as the company launched its first metered dose inhaler (MDI) in India. While the launch strengthens Cadila’s respiratory portfolio, analysts say more triggers are falling into place to drive earnings.

In the US, Cadila is expected to gain from improvement in realisation for its product range led by drug shortages. Already, it has been gaining market share. “In one of its most integrated key products, mesalamine (Lialda generics) — used for treating ulcerative colitis, Cadila’s share has improved to 70 per cent from 55 per cent in January